Literature DB >> 18541113

Recent advances in the genetics of dementia with lewy bodies.

Vincenzo Bonifati1.   

Abstract

In the past few years, mutations have been identified in the genes encoding alpha-synuclein, leucine-rich repeat kinase 2, and glucocerebrosidase in some patients with dementia with Lewy bodies (DLB). Furthermore, a novel locus for familial DLB has been mapped to chromosome 2q35-q36. Collectively, these discoveries highlight a substantial overlap between the known genetic determinants of Parkinson's disease and DLB, as well as the presence of profound etiologic heterogeneity in Lewy body disorders.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18541113     DOI： 10.1007/s11910-008-0030-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  30 in total

1.  Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.

Authors:  O Goker-Alpan; B I Giasson; M J Eblan; J Nguyen; H I Hurtig; V M-Y Lee; J Q Trojanowski; E Sidransky
Journal:  Neurology       Date:  2006-06-21       Impact factor: 9.910

2.  Lrrk2 and Lewy body disease.

Authors:  Owen A Ross; Mathias Toft; Andrew J Whittle; Joseph L Johnson; Spiridon Papapetropoulos; Deborah C Mash; Irene Litvan; Mark F Gordon; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

3.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

Authors:  J Fuchs; C Nilsson; J Kachergus; M Munz; E-M Larsson; B Schüle; J W Langston; F A Middleton; O A Ross; M Hulihan; T Gasser; M J Farrer
Journal:  Neurology       Date:  2007-01-24       Impact factor: 9.910

4.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.

Authors:  M Hashimoto; E Rockenstein; M Mante; M Mallory; E Masliah
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

Review 5.  How to diagnose dementia with Lewy bodies: state of the art.

Authors:  Felix Geser; Gregor K Wenning; Werner Poewe; Ian McKeith
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

6.  Clinical genetic analysis of Parkinson's disease in the Contursi kindred.

Authors:  L I Golbe; G Di Iorio; G Sanges; A M Lazzarini; S La Sala; V Bonavita; R C Duvoisin
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

7.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

8.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

Authors:  P Ibáñez; A-M Bonnet; B Débarges; E Lohmann; F Tison; P Pollak; Y Agid; A Dürr; A Brice
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

9.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

Authors:  Ian G McKeith
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472
View more
  2 in total

Review 1.  Genetics of dementia.

Authors:  Henry L Paulson; Indu Igo
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

Review 2.  Recent insights into the molecular genetics of dementia.

Authors:  Rosa Rademakers; Anne Rovelet-Lecrux
Journal:  Trends Neurosci       Date:  2009-07-27       Impact factor: 13.837
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.